I was recently asked if I thought IMGN was headed for a buyout, I said I certainly hope not. After all these years I believe we're closing in on success on a few different products that could take the stock price to levels never seen before. I would hope that the recent increase in price is in anticipation that we'll pass the futility check with no problem, and perhaps that will bring the ROW partnership IMGN has openly said they want for IMGN853.
I certainly don't know what such a partnership could bring in immediately, as such a partnership could be constructed in so many ways. The one extreme would have IMGN receiving a huge payment upfront for ROW rights, but practically nothing on sales revenue. The other extreme would have IMGN receiving little up front, but a major part of sales revenue. I suspect they'll come up with a partnership that's somewhere in the middle.
In that the IGN drugs in trial, or coming into trial are already partnered with Jazz, the only real question beyond what the data shows, is whether Jazz chooses to opt in when they have their options to do so. As I remember it, that's before they enter a Phase 3 Trial, and again for a much higher price once they're ready to file the BLA. Certainly we're talking a few year's at least, but their will be many times to observe data between now and then, and if the data looks good, the share price should reflect it, likewise if it doesn't.
Gary |
